Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis has signed an exclusive licensing agreement with Blanver for BIO101 in Latin America, potentially worth up to €108 million. Blanver will oversee the registration, marketing, and commercialization of the drug.

The agreement includes initial payments and future milestone payments, alongside double-digit royalties on sales. Targets include obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy.

Both companies will also collaborate on manufacturing and clinical development. Blanver's existing network will cover distribution across Latin America, extending beyond Brazil to countries like Mexico, Argentina, and Colombia.

This partnership aims to expand BIO101's reach, supported by positive clinical outcomes in various indications. It aligns with Biophytis' strategic goals, especially for obesity treatments, in a rapidly growing pharmaceutical market.